Rachel Vatnsdal
Stock Analyst at JP Morgan
(3.33)
# 993
Out of 5,146 analysts
68
Total ratings
53.19%
Success rate
16.24%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Maintains: Neutral | $100 → $105 | $97.57 | +7.62% | 5 | Feb 3, 2026 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $17 → $20 | $16.21 | +23.38% | 6 | Nov 6, 2025 | |
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $81.91 | -7.22% | 4 | Aug 7, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $9.06 | +54.53% | 1 | Aug 4, 2025 | |
| ILMN Illumina | Maintains: Neutral | $85 → $100 | $121.87 | -17.95% | 1 | Aug 1, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $18.31 | +69.31% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $19.66 | -54.22% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $49.58 | -33.44% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $132.14 | +43.79% | 6 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $29.59 | -35.79% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $380 → $390 | $319.44 | +22.09% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $53.71 | +2.40% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $95.27 | -42.27% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $124.72 | +28.29% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $513.68 | +30.43% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $4.78 | +318.41% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,379.91 | +1.46% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.63 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $39.89 | +125.62% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $209.52 | +28.87% | 4 | Dec 20, 2023 |
Revvity
Feb 3, 2026
Maintains: Neutral
Price Target: $100 → $105
Current: $97.57
Upside: +7.62%
Adaptive Biotechnologies
Nov 6, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $16.21
Upside: +23.38%
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $81.91
Upside: -7.22%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $9.06
Upside: +54.53%
Illumina
Aug 1, 2025
Maintains: Neutral
Price Target: $85 → $100
Current: $121.87
Upside: -17.95%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $18.31
Upside: +69.31%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $19.66
Upside: -54.22%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $49.58
Upside: -33.44%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $132.14
Upside: +43.79%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $29.59
Upside: -35.79%
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $319.44
Upside: +22.09%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $53.71
Upside: +2.40%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $95.27
Upside: -42.27%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $124.72
Upside: +28.29%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $513.68
Upside: +30.43%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $4.78
Upside: +318.41%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,379.91
Upside: +1.46%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.63
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $39.89
Upside: +125.62%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $209.52
Upside: +28.87%